Biotech Values

[rkrw]

I've heard the mexican physician is well respected. However, as a bio investor, it's important to be cautious in interpreting open label studies. Dew has explained the risks very well, selection bias, excellent care, pbo effect, trying harder to read the letters, who knows? Good or bad, the first pbo controlled data is the seminal event for genr.